Paris, France-based immuno-oncology specialist Biomunex Pharmaceuticals has appointed Dr Sebastian Amigorena and Dr Dragan Grabulovski as key scientific advisor and key strategic advisor, respectively.
Dr Amigorena (pictured right) is currently a research director at Le Centre National de la Recherché Scientifique (CNRS) and is director of the Inserm Immunity and Cancer Unit at the Institut Curie in Paris.
In his role as scientific advisory, he will help the company to leverage its ‘Plug-and-Play’ antibody platform for the development of Biomunex’s immunotherapeutics pipeline.
Meanwhile, Dr Grabulovski (pictured left) is a pharmaceutical biotechnology advisor at Grabulovski Consulting Services, having previously served as chief scientific officer of Covagen, which he co-founded.
Prior to Covagen’s sales to Johnson & Johnson in 2014, Dr Grabulovski was responsible for the Swiss biotech’s research and development strategy, including its Fynomer technology.
Dr Pierre-Emmanuel Gerard, chief executive officer at Biomunex, said: “We are very pleased to welcome Dr Amigorena and Dr Grabulovski as key advisors.
“As international key opinion leaders they will play an instrumental role as we advance our first oncology programmes into pre-clinical and clinical development.”